Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis

Abstract

The CADTH Health Technology Expert Review Panel (HTERP) offers the following guidance to help health systems prepare for potential uptake of autologous hematopoietic stem cell transplantation (AHSCT) for the treatment of multiple sclerosis (MS) should emerging evidence continue to signal clinical benefit and an appropriate safety profile: Develop and implement systematic strategies for offering monitoring and follow-up care closer to home for individuals currently offered AHSCT for the treatment of MS and those who may be offered AHSCT for the treatment of MS in the future. Build interprovincial/territorial agreements and other mechanisms that include consideration of financial and logistical support when travel and short-term relocation are required to access AHSCT for MS. Develop clear and transparent guidelines and protocols, including related training, that are acceptable for potential AHSCT candidates, their caregivers, and their clinicians. Ensure transplant centre capacity, budget, and other required resources. Support novel relationships and collaboration among MS and AHSCT health care professionals who would be involved in delivering care. Ensure equity in access and equitable approaches to care delivery are guiding principles in providing AHSCT for treating MS.